• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Utility of plasma MicroRNA profiling as diagnostic biomarker in immune system activation and inflammation and early predictor of severity

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Dec 30.
doi: 10.1038/s41598-025-29736-2. Online ahead of print. Utility of plasma MicroRNA profiling as diagnostic biomarker in immune system activation and inflammation and early predictor of severity in patients with COVID-19

Martina Schiavello[SUP] #[/SUP][SUP] 1 [/SUP], Barbara Vizio[SUP] #[/SUP][SUP] 1 [/SUP], Tiziana Sanavia[SUP] 2 [/SUP], Ornella Bosco[SUP] 1 [/SUP], Chiara Dini[SUP] 1 [/SUP], Paolo Cagna Vallino[SUP] 1 3 [/SUP], Emanuele Pivetta[SUP] 1 3 [/SUP], Fulvio Morello[SUP] 1 3 [/SUP], Piero Fariselli[SUP] 2 [/SUP], Giuseppe Montrucchio[SUP] 1 [/SUP], Enrico Lupia[SUP] 4 [/SUP]



Affiliations
Abstract

The clinical course of Coronavirus disease 2019 (COVID-19) ranges from mild symptoms to severe complications, including respiratory failure and thromboembolic events. MicroRNAs (miRNAs) are small non-coding RNAs involved in gene regulation and may serve as biomarkers. This study aimed to identify plasma miRNAs that could serve as biomarkers for diagnosing immune system disorders and inflammation, and for prognostic stratification of patients with COVID-19. We enrolled 40 patients with suspected COVID-19 at Emergency Room admission; infection was confirmed in 30 of them. Ten non-COVID-19 patients and 10 healthy subjects were included for comparison. Among the COVID-19 group, 26 hospitalized patients were followed and stratified by disease severity (good vs. poor prognosis). Plasma miRNA profiling and single-tube validation were performed using qRT-PCR, supported by in silico miRNA-mRNA prediction and pathway enrichment analysis. Expressions of miR-199a-5p, miR-142-3p, miR-133a-3p and miR-545-3p were higher in COVID-19 patients vs. healthy subjects. Moreover, miR-133a-3p and miR-545-3p were increased in COVID-19 vs. non-COVID-19 patients. miR-423-3p, miR-106b-5p, miR-142-3p and miR-369-3p were significantly elevated in patients who later developed respiratory failure. Bioinformatics analysis suggested that these miRNAs are involved in immune and inflammation pathways. Plasma miRNA profiling may be a promising non-invasive tool for COVID-19 diagnosis and prediction of severity.

Keywords: Bioinformatics; Biomarkers; COVID-19; MiRNA profiling.

 
Back
Top